The Hetero Ring Has At Least Seven Members Patents (Class 514/450)
  • Patent number: 10292388
    Abstract: The invention relates to the use of a compound of formula (I) or a salt thereof for combating animal pests, where the symbols and indices are defined in the specification.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: May 21, 2019
    Assignee: BASF SE
    Inventors: Ralph Paulini, Matthias Pohlman, Sebastian Soergel, Henricus Maria Martinus Bastiaans, Sarah Thompson, Cecille Ebuenga Doyog, Anna Malveda Umali, Rhoel Suiza Cosare, Christopher Palmer, Takeo Hokama
  • Patent number: 10189794
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: January 29, 2019
    Assignees: Celgene CAR LLC, Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • Patent number: 10183934
    Abstract: The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II: where R, L, X1, X2, X3, X4, X5, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: January 22, 2019
    Assignee: Forma Therapeutics, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Aleksandra Rudnitskaya, David R. Lancia, Jr.
  • Patent number: 10137141
    Abstract: A tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof, and a pharmaceutical composition, containing a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof, are provided for use in the oral treatment of Clostridium difficile infections (CDI) or Clostridium difficile associated diarrhea or disease (CDAD) in a patient in accordance with a dosage regimen selected from the group consisting of: i. Administering 200 mg of the tiacumicin compound BID for 5 days followed by 5 days of rest and then 200 mg once daily for a further 10 days and ii. Administering 200 mg of the tiacumicin compound BID for 5 days followed by a single 200 mg every other day for 20 days.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: November 27, 2018
    Assignee: Astellas Pharma Europe Ltd.
    Inventors: Andreas Johannis Karas, Christopher Mark Longshaw
  • Patent number: 10137106
    Abstract: The present disclosure is directed to compositions comprising bryostatin-1, and methods comprising administering a composition comprising bryostatin-1, to treat Niemann-Pick Type C in a subject in need thereof.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: November 27, 2018
    Assignee: Cognitive Research Enterprises, Inc.
    Inventor: Daniel L. Alkon
  • Patent number: 9918972
    Abstract: Methods of treating cancer, such as leukemia, via administration of therapeutically effective amounts of artemisinins and second agents are detailed herein. The artemisinins include artesunate, dihydroartemisinin, artemether, arteether, artelinate, and ART-838. The second agents include BCL-2 inhibitors such as ABT-199, ABT-263, and ABT-737; kinase inhibitors such as lestaurtinib, midostaurin, and sorafenib; and anti-neoplastic agents such as cytarabine, doxorubicin, etoposide, cyclophosphamide, triplotide, vinorelbine, cisplatin, and rituximab.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: March 20, 2018
    Assignees: THE UNIVERSITY OF MARYLAND, BALTIMORE, THE JOHNS HOPKINS UNIVERSITY
    Inventors: Curt Civin, Xiaochun Chen, Jennifer Fox, Gary Posner, Michelle Rudek
  • Patent number: 9833435
    Abstract: The present disclosure is directed to compositions comprising bryostatin-1, and methods comprising administering a composition comprising bryostatin-1, to treat Niemann-Pick Type C in a subject in need thereof.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: December 5, 2017
    Assignee: Blanchette Rockefeller Neurosciences Institute
    Inventor: Daniel L. Alkon
  • Patent number: 9789070
    Abstract: A sheet pack comprising an absorbent layer impregnated with a treatment composition containing at least one ingredient that when topically applied to skin stimulates a gene that is variably expressed over a 24 hour period in native untreated skin cells; the sheet pack contained in a package with user instructions to topically apply the sheet pack to the skin at a time when the gene that is stimulated by the ingredient is being maximally expressed in native untreated skin cells; and methods for treating skin and methods for making a sheet pack.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: October 17, 2017
    Assignee: ELC Management LLC
    Inventors: Anne Carullo, Jennifer Palmer Quintano, Joyce Kassouf, Nadine Pernodet, Donald Collins, Dawn Layman, Allan Hafkin, Osvaldo Fontanet
  • Patent number: 9782424
    Abstract: The present invention includes a composition comprising an effective amount of an avermectin compound, and an effective amount of an imidazole antifungal compound, and/or an effective amount of non-steroidal anti-inflammatory drug (NSAID) or suitable pharmaceutically acceptable salts thereof, for use in the inhibition of tumor growth and treating urothelial, colorectal, prostate and/or breast cancers. Furthermore, the invention includes a method of inhibiting tumor growth and treating said cancers comprising administering to a subject in need thereof an effective amount of said composition.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: October 10, 2017
    Assignee: ECTIN RESEARCH AB
    Inventors: Christer Edlund, Peter Falk, Marie-Lois Ivarsson
  • Patent number: 9707174
    Abstract: An aqueous ophthalmic solution containing a relatively high concentration of olopatadine in solubilized form is provided. The solution comprises a combination of at least two non-ionic surfactants and is essentially devoid of cyclodextrins. The solution is useful for providing enhanced relief from symptoms of ocular allergic disorders (e.g. conjunctivitis).
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: July 18, 2017
    Assignee: Somerset Therapeutics LLC
    Inventor: Bala Chandran Nayar
  • Patent number: 9707254
    Abstract: A method for preventing and treating one or more disease states including the steps of altering the diet of an individual and then administering a drug to the individual. Plasma vitamin C level is reduced from a first level to a second level that is lower than the first level, such that a pharmacological response of the body of the individual to a drug at the first level is different from the pharmacological response of the body of said individual to the drug at the second level.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: July 18, 2017
    Inventor: Harold Edward Siess
  • Patent number: 9656945
    Abstract: The invention relates to compounds of general formula I, (I), wherein R is wherein R is aryl substituted by R3; or R is (C3-Ci3)-cycloalkyl, (C3-Ci3)-cycloalkenyl or (C7-Ci3)-cycloalkynyl optionally substituted by R4; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: May 23, 2017
    Assignee: LEO LABORATORIES LIMITED
    Inventors: Gunnar Grue-Sørensen, Xifu Liang, Thomas Högberg, Kristoffer Månsson, Per Vedsø
  • Patent number: 9539235
    Abstract: The present invention relates to compositions and methods to modulate ?-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: January 10, 2017
    Assignee: COGNITIVE RESEARCH ENTERPRISES, INC
    Inventors: Rene Etcheberrigaray, Daniel L. Alkon
  • Patent number: 9498463
    Abstract: Disclosed herein are seventeen new compounds obtained from an acetone-extracted product of gamboge resin. The seventeen new compounds have activities in inhibiting the growth of tumor/cancer cells.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: November 22, 2016
    Assignee: Taiwan Sunpan Biotechnology Development Co., Ltd.
    Inventor: Sen-Bin Lee
  • Patent number: 9403841
    Abstract: The present invention relates to novel chemical compounds, to methods for synthesis of such compounds, and to the use of these novel compounds in the synthesis of other chemical compounds that, inter alia, may be used in the treatment of sexual dysfunction, and for eliciting enhancing effects on sexual behavior. The invention also relates to remarkable biological properties of the novel compounds in their capacity of inducing aggressive behavior.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: August 2, 2016
    Assignee: DICOTYLEDON AB
    Inventors: Jarl Wikberg, Aigars Jirgensons, Edvards Liepinsh
  • Patent number: 9393228
    Abstract: The present invention relates to the combination of a selective late sodium current blocker and a selective, specific sinus If current inhibitor, and to the pharmaceutical compositions containing said combination.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: July 19, 2016
    Assignee: PIERRE FABRE MEDICAMENT
    Inventor: Bruno Le Grand
  • Patent number: 9388124
    Abstract: The invention relates to compounds of general formula (I) wherein R is (C1-C7)alkyl, (C2-C7)alkenyl or (C2-C7)alkynyl; wherein R is substituted with R1; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: July 12, 2016
    Assignee: LEO LABORATORIES LIMITED
    Inventors: Gunnar Grue-Sørensen, Xifu Liang, Thomas Högberg
  • Patent number: 9346781
    Abstract: The invention provides compounds useful as anti-cancer agents.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: May 24, 2016
    Assignee: University of Iowa Research Foundation
    Inventors: Zhendong Jin, Lei Chen
  • Patent number: 9289411
    Abstract: Provided is a novel anti-HCV agent including as an active ingredient a peroxide derivative represented by the general formula (I). In the general formula (I), C represents an alicyclic hydrocarbon ring group which may be substituted, n represents an integer of from 1 to 6, and R represents a hydrogen atom or a hydroxyalkyl group. The peroxide derivative exhibits potent anti-HCV activity by remarkably suppressing HCV-RNA replication.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: March 22, 2016
    Assignee: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
    Inventors: Nobuyuki Kato, Masanori Ikeda, Yusuke Wataya, Hye-Sook Kim, Hiroyuki Doi
  • Patent number: 9211275
    Abstract: The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic ?-hydroxybutyrate or D-?-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic ?-hydroxybutyrate or D-?-hydroxybutyrate, esters of D-?-hydroxybutyrate, oligomers of D-?-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject.
    Type: Grant
    Filed: January 5, 2009
    Date of Patent: December 15, 2015
    Assignees: ISIS INNOVATION LTD., The United States of America, as represented by the Secretary of the Department of Health and Human Services (DHSS)
    Inventors: Kieran Clarke, Richard Lewis Veech
  • Patent number: 9187752
    Abstract: The invention relates to modifying plasmid origins of replication to create hybrid origins of replication containing nucleotide sequences from more than one plasmid. The invention also relates to a modified origin of replication cassette that is portable or exchangeable due to the creation of multiple cloning sites flanking the origin of replication. Methods and plasmids for use in exchanging origins of replication are disclosed. Such modified or hybrid plasmids provide useful cloning tools that allow for regulation of the level of expression of a desired protein.
    Type: Grant
    Filed: September 13, 2006
    Date of Patent: November 17, 2015
    Assignee: Monsanto Technology LLC
    Inventors: Gregg Bogosian, Julia P. O'Neil, Hong Q. Smith
  • Patent number: 9138422
    Abstract: The present invention provides a method for inhibiting the growth of cancer stem cells, particularly colorectal cancer stem cells, liver cancer stem cells, lung cancer stem cells or breast cancer stem cells, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of antimycin A or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: September 22, 2015
    Inventors: Chi-Ying F. Huang, Chi-Tai Yeh, Chun-Hung Wu, Yu-Wen Liu
  • Patent number: 9107898
    Abstract: Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: August 18, 2015
    Assignee: Pernix Sleep, Inc.
    Inventors: Roberta L. Rogowski, Susan E. Dube, Philip Jochelson, Neil B. Kavey
  • Patent number: 9089543
    Abstract: The present invention relates to an anti-inflammatory use of macrolactin compounds such as macrolactin A, 7-O-malonyl macrolactin A and 7-O-succinyl macrolactin A, which are produced from a novel Bacillus strain of Bacillus polyfermenticus KJS-2 (KCCM10769P). The macrolactin compounds provided by the present invention were confirmed to greatly suppress the expression and formation of inducible nitric oxide synthetase (iNOS) and cyclooxygenase-2 (COX-2) which are proteins related to the formation of inflammatory mediators, and to accordingly inhibit the formation of nitric oxide (NO) and of prostaglandin E2 (PGE2) which are the metabolites of the proteins. In addition, the macrolactin compounds provided by the present invention were confirmed to have excellent effects in inhibiting the formation of tumor necrosis factor-alpha (TNF-?), interleukin-1? (IL-1?), interleukin-6 (IL-6) and granulocyte macrophage colony-stimulating factor (GM-CSF), which are pro-inflammatory cytokines.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: July 28, 2015
    Assignee: DAEWOO PHARMACEUTICAL IND. CO., LTD.
    Inventors: Young-Hoon Ji, Dong-Hee Kim, Jae-Seon Kang, Chun-Gyu Kim, Sung-Uk Chung, Sung-Woo Hwang, Kyung-Ran Kang
  • Patent number: 9062020
    Abstract: Disclosed is a compound of formula 1, as shown below, where R1, R2, R3, R4, R5, R6 and R7 are as described herein. Also, disclosed is a process for the preparation of compounds of formula 1, and intermediates used therein. The compound of formula 1 can be useful for preparation of halichondrin analogs such as Eribulin.
    Type: Grant
    Filed: December 24, 2012
    Date of Patent: June 23, 2015
    Assignee: ALPHORA RESEARCH INC.
    Inventors: Fabio E. S. Souza, Alena Rudolph, Ming Pan, Boris Gorin, Dino Alberico
  • Patent number: 9060985
    Abstract: The present invention relates to rosmarinic acid and to the derivatives thereof, expressed by the compounds of general formula (I), for the use thereof to prevent and/or treat disorders caused by ciguatoxin poisoning and for preparing a pharmaceutical composition for preventing and/or treating disorders caused by ciguatoxin poisoning.
    Type: Grant
    Filed: July 21, 2010
    Date of Patent: June 23, 2015
    Assignees: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT, INSTITUT LOUIS MALARDE
    Inventors: Dominique Laurent, Serge Pauillac, Mireille Chinain, Taiana Darius, Shilpa Kumar-Roine
  • Patent number: 9051302
    Abstract: Disclosed are macrocyclic compounds of formulae I, I?, II, II?, III, III?, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: June 9, 2015
    Assignee: UNIVERSITE DE STRASBOURG
    Inventors: Nicolas Winssinger, Sofia Barluenga, Martin Karplus
  • Patent number: 9044453
    Abstract: This invention provides for novel antiparasitic and pesticidal forms of moxidectin, including a long-acting polymeric implant. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections in animals.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: June 2, 2015
    Assignee: MERIAL, INC.
    Inventors: Susan Mancini Cady, Baoqing Ma, Robert Clark Chapman, Chunhua Yang, Uday Jain
  • Patent number: 9034917
    Abstract: The present invention relates generally to the field of lipids and in particular aims at improving lipid absorption, for example under conditions of lipid maldigestion or malabsorption. One embodiment of the present invention relates to a composition comprising a sn-2 monoacylglycerol derivative, wherein the sn-1 and sn-3 positions are blocked by protective groups. The acyl group may be a fatty acid, for example one with anti-inflammatory properties.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: May 19, 2015
    Assignee: Nestec S.A.
    Inventors: Bruce Bistrian, Frederic Destaillats, Cristina Cruz-Hernandez, Fabiola Dionisi, Isabelle Masserey-Elmelegy, Manuel Oliveira, Julie Celine Moulin
  • Publication number: 20150133535
    Abstract: Provided herein, inter alia, are anticancer polyketides. The uses of the polyketides described herein include treatment of cancer, for example, through regulation of the spliceosome and detection of spliceosome inhibition.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 14, 2015
    Inventors: Michael D. Burkart, James J. La Clair, Brian D. Jones, Alexander Mandel, Reymundo Villa, Januario E. Castro, Manoj Kumar Kashyap, Deepak Kumar
  • Publication number: 20150119455
    Abstract: Stable formulations of Olopatadine, methods of making such formulations and methods of treatment using such formulations are provided.
    Type: Application
    Filed: August 27, 2014
    Publication date: April 30, 2015
    Applicant: Nephron Pharmaceuticals Corporation
    Inventors: Eric Primelles-Perez, Jessica R. Hoover
  • Patent number: 9018178
    Abstract: The present invention provides an aqueous antifungal composition comprising a polyene antifungal compound and a thickening agent. The composition can be used in the protection against the development of fungi on food, feed and agricultural products.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: April 28, 2015
    Assignee: DSM IP Assets B.V.
    Inventors: Pim Van Hee, Laurentius Cornelis Adrianus Van Santen, John Mark Faragher
  • Publication number: 20150099015
    Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.
    Type: Application
    Filed: November 24, 2014
    Publication date: April 9, 2015
    Inventor: Guochuan Emil TSAI
  • Publication number: 20150094339
    Abstract: The invention relates to compounds of macrocyclic picolinamides of Formula I suitable to control or prevent growth of fungi.
    Type: Application
    Filed: September 29, 2014
    Publication date: April 2, 2015
    Inventors: Timothy P. Martin, Kevin G. Meyer, Benjamin Nugent, Chenglin Yao, W. John Owen, Anne M. Wilson, Ian O'Callaghan, Jeremy Wilmot, Johnathan E. DeLorbe, William Dent, III
  • Publication number: 20150094363
    Abstract: Embodiments of the present invention are directed to methods and dosage forms for treating inflammation and rejection in transplantation injuries with Bryostatin-1, Bryostatin-1 analogs and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 2, 2015
    Inventors: Jonathan Steven Alexander, April C. Carpenter, Trevor Percival Castor
  • Publication number: 20150094341
    Abstract: The invention relates to compounds of macrocyclic picolinamides of Formula I suitable to control or prevent growth of fungi.
    Type: Application
    Filed: September 29, 2014
    Publication date: April 2, 2015
    Inventors: Fangzheng Li, Kevin G. Meyer, James M. Renga, Chenglin Yao, Jeremy Wilmot, Jessica Herrick, Karla Bravo-Altamirano, Timothy Boebel
  • Publication number: 20150094340
    Abstract: The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides.
    Type: Application
    Filed: September 29, 2014
    Publication date: April 2, 2015
    Inventors: Timothy P. Martin, Kevin G. Meyer, Benjamin Nugent, Chenglin Yao, W. John Owen, Anne M. Wilson, Ian O'Callaghan, Jeremy Wilmot, Johnathan E. DeLorbe, William Dent, III
  • Publication number: 20150094281
    Abstract: The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides.
    Type: Application
    Filed: September 29, 2014
    Publication date: April 2, 2015
    Inventors: Fangzheng Li, Kevin G. Meyer, James M. Renga, Chenglin Yao, Jeremy Wilmot, Jessica Herrick, Karla Bravo-Altamirano, Timothy Boebel
  • Publication number: 20150087610
    Abstract: The present invention provides methods and compositions for modifying fertility in a male mammalian subject by contacting the subject's testis cells, germ cells or sperm with a sufficient amount of a composition comprising a ligand that binds, activates, or inhibits activation of, a TAS2R receptor expressed on the cells. Also described are methods for screening a test molecule for its effect on fertility by examining changes in male germ cells, testis cells or sperm resulting from contact with a molecule that binds, activates, or inhibits activation of, a TAS2R receptor expressed on the cells. Compositions for modifying fertility in a mammalian subject, e.g., contraceptive products, include a ligand that binds, inhibits or activates a TAS2R receptor in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 18, 2013
    Publication date: March 26, 2015
    Applicant: Monell Chemcial Senses Center
    Inventors: Liquan Huang, Jiang Xu
  • Patent number: 8980896
    Abstract: The present invention provides formulations which may comprise macrocyclic lactones and at least one spirodioxepinoindole derivative or a spirooxepinoindole derivative for combating parasites in birds and mammals. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: March 17, 2015
    Assignee: Merial, Inc.
    Inventors: Robert Holmes, Majid Razzak
  • Patent number: 8980939
    Abstract: A process for the preparation of olopatadine hydrochloride starting from an advanced intermediate.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: March 17, 2015
    Assignee: F.I.S. Fabbrica Italiana Sintetici S.p.A.
    Inventors: Andrea Castellin, Clark Ferrari, Marco Galvagni
  • Publication number: 20150072979
    Abstract: The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisinin derivatives having anti-viral activity.
    Type: Application
    Filed: April 17, 2013
    Publication date: March 12, 2015
    Applicants: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT
    Inventors: Richard K. Haynes, Dana G. Wolf
  • Publication number: 20150073042
    Abstract: The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.
    Type: Application
    Filed: September 5, 2014
    Publication date: March 12, 2015
    Applicant: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • Publication number: 20150065565
    Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Applicant: Pfizer Inc.
    Inventor: Vincent Mascitti
  • Patent number: 8957056
    Abstract: In one aspect, the present invention provides a method for treating colon and/or ovarian cancer in a subject comprising administering to a subject in need thereof a compound of general formula (I): wherein R1-R6, R, -R, Q, Y1, Y2 and n are as defined herein, wherein the compound is present in an amount effective to inhibit colon and/or ovarian tumor metastasis.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: February 17, 2015
    Assignee: Sloan-Kettering Instiute for Cancer Research
    Inventors: Samuel J. Danishefsky, Christoph Gaul, Jón T. Njardarson, Malcolm A. S. Moore, Kaida Wu, David C. Dorn, Mihirbaran Mandal
  • Patent number: 8957107
    Abstract: Methods of treating disorders mediated by ?-catenin comprising administration of Nefopam compounds are provided In particular, the treatment of disorders arising from excessive or undesired expression of ?-catenin is contemplated Said compounds include Nefopam, analogues thereof, prodaigs thereof, and salts and solvates of Nefopam The ?-catenin mediated disorders are preferably selected from the group consisting of fibroproliferative disorders (such as scars, aggressive fibramtoses, and fibroses) and cancer (such as colon cancer, melanoma, liver cancer, ovarian cancer, endometrial cancer, medullobalstoma pilomatricomas, and prostate cancer)
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: February 17, 2015
    Assignee: The Hospital for Sick Children
    Inventors: Benjamin A. Alman, Raymond Poon, Helen Hong
  • Publication number: 20150038565
    Abstract: The present invention relates to a long-acting composition for the treatment of an animal in need thereof wherein the composition includes a therapeutically effective amount of a bioactive agent, characterised in that the composition includes a non-aqueous carrier and a solvent system comprising castor oil and at least one cyclic amide.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 5, 2015
    Inventors: Fadil Al Alawi, Karthigeyan Nanjan
  • Publication number: 20150038566
    Abstract: The invention provides novel compounds of Formulas (I)-(IV), as described herein. Also provided are compositions of these compounds, method of making the compounds, and methods of using the compounds. The compounds can be used to regulate cholesterol homeostasis and to treat conditions and diseases associated with cholesterol homeostasis, including lysosomal lipid storage disorders such as Niemann-Pick Disease type C.
    Type: Application
    Filed: October 20, 2014
    Publication date: February 5, 2015
    Applicant: UNIVERSITY OF NOTRE DAME DU LAC
    Inventor: Richard Taylor
  • Patent number: 8945597
    Abstract: The invention generally relates to environmental friendly pesticide compounds, formulations, methods of preparation and application and utilities thereof. More particularly, the invention relates to pesticide compounds and formulations that include terpenes or terpenoids having chemical formula of (C5H8)n, and its derivatives and analogs thereof, as active insecticidal ingredients; certain botanical essential oils as synergists, and other select ingredients as additives.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: February 3, 2015
    Inventor: Tao Zhong
  • Publication number: 20150030583
    Abstract: The discovery of clonally pure populations of serosal cancer stem cells (CSCs) as well as methods of producing CSCs, culturing the CSCs and using them in screening assays, has lead to the development of methods of treating serosal and ovarian cancers by targeting removal or inhibition of the glycocalyx coat surrounding such cells, and includes combination therapies using particular chemotherapeutics in conjunction with glycocalyx inhibitors, as well as the same new chemotherapy treatments without targeting the glycocalyx, where the chemotherapeutic agent is any one of LBH-589 (Panobinostat), NVP-AUY922, LAQ824 (NVP-LAQ824, Dacinostat), colchicine, brefeldin A, diphenyleneiodonium chloride, any combination thereof or another agent identified herein. These treatment methods of the invention can also be used in combination with radiation treatment or other conventional cancer therapy.
    Type: Application
    Filed: March 30, 2012
    Publication date: January 29, 2015
    Applicant: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Malcolm A.S. Moore, Server A. Ertem